nab-Sirolimus improves mTOR pathway suppression and antitumor activity versus oral mTOR inhibitors in PTEN null bladder cancer (UMUC3) and TSC2 null liver cancer (SNU398) xenografts

Shihe Hou,Heng Du, Anita N. Schmid,David J. Kwiatkowski, Neil P. Desai

MOLECULAR CANCER THERAPEUTICS(2021)

引用 1|浏览0
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要